Author

Li Ren

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:perturbation response prediction· 1 Research Focus:protein folding & dynamics· 1 Approach:statistical model· 1

Frequent Co-Authors

Ana Orive-RamosiD· 1 shared Beau BaarsiD· 1 shared Bijaya GaireiD· 1 shared Dalton DacusiD· 1 shared Dexiang Zhu· 1 shared Evangelia MatenoglouiD· 1 shared Evripidis GavathiotisiD· 1 shared Frank P. McCormickiD· 1 shared

Activity by Year

2018-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Ana Orive-RamosORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Binding kinetics enable tumor-selective MAPK and growth suppression by a Type 1 RAF Inhibitor

Mathieu Desaunay, Tara Peters, Evangelia Matenoglou, Beau Baars, Bijaya Gaire, Ana Orive-Ramos, Li Ren, Joseph P. Lyssikatos, Michael Burkard, Dalton Dacus, Matthew J. Sale, Stuart A. Aaronson, Frank P. McCormick, Evripidis Gavathiotis, Stefan David Gross, Poulikos I. Poulikakos

This study identifies ELV-3111, a Type 1 RAF inhibitor that selectively suppresses MAPK and tumor growth by exploiting distinct binding kinetics, showing efficacy in RAS-mutant and BRAF-mutant models.

bioRxiv · Oct 6, 2026 · PreprintCancer Biology

Tumour purity as a prognostic factor in colon cancer

Yihao Mao, Qingyang Feng, Peng Zheng, Liangliang Yang, Tianyu Liu, Yuqiu Xu, Dexiang Zhu, Wenju Chang, Meiling Ji, Yongjiu Tu, Li Ren, Ye Wei, Guodong He, Jianmin Xu

This study investigates tumour purity in colon cancer, finding it correlates with prognosis, mutation burden, and immune microenvironment, with low purity linked to worse survival and less chemotherapy benefit.

bioRxiv · Feb 12, 2018 · PreprintCancer Biology